U.S. Food and Drug Commissioner Marty Makary confirmed on Wednesday that his agency’s review of the drug responsible for a majority of the nation’s abortions is underway and will be publicized as soon as results are finalized.
As stories of women suffering injuries and even death after taking abortion pills without medical supervision gained traction, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. pledged that the administration would “study the safety of mifepristone.” By March 2025, Makary also promised “to review the ongoing data.”
News of the review, however, remained sparse and vague for most of 2025, prompting Congress and pro-life organizations to pressure the FDA to roll back Biden-era expansions that make it easier for people to obtain mifepristone via mail or a drug store pharmacy without a doctor visit or medical oversight. Polling suggesting a majority of likely voters also want the FDA to protect women from the dangers of abortion pills, also made an appearance shortly after both Kennedy and Makary announced the FDA “is conducting its own review of the evidence.”
Read More on The Federalist